Aardvark Therapeutics (NASDAQ:AARD) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut shares of Aardvark Therapeutics (NASDAQ:AARD) from a hold rating to a sell rating in a report published on Saturday.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Aardvark Therapeutics in a research note on Tuesday, April 1st. Morgan Stanley started coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They issued an “overweight” rating and a $29.00 price objective for the company. Royal Bank of Canada cut their price target on Aardvark Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. Finally, Bank of America lifted their target price on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.25.

Aardvark Therapeutics Stock Performance

NASDAQ:AARD opened at $10.74 on Friday. The stock has a 50 day moving average price of $9.83. Aardvark Therapeutics has a 52 week low of $4.88 and a 52 week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01).

Hedge Funds Weigh In On Aardvark Therapeutics

Several hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. acquired a new stake in Aardvark Therapeutics during the 1st quarter valued at $153,000. Cormorant Asset Management LP acquired a new stake in Aardvark Therapeutics during the first quarter worth approximately $6,009,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Aardvark Therapeutics in the first quarter worth $1,878,000. Braidwell LP bought a new position in Aardvark Therapeutics in the 1st quarter valued at about $3,755,000. Finally, Walleye Capital LLC acquired a new position in Aardvark Therapeutics during the first quarter valued at approximately $88,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.